Live Quote · NASDAQCYTHealthcare· Biotechnology

Cyteir Therapeutics, Inc.

$3.02 2.27%($-0.07)
TickerSpark Score
58/100
Mixed
93
Valuation
40
Profitability
15
Growth
84
Health
60
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYT research report →

52-Week Range89% of range
Low
$1.65
Current
$3.02
High
$3.19
Company Overviewcyteir.com

About the company

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing.

CEO
Markus F. Renschler
IPO
2021
Employees
46
HQ
Lexington, MA, US

Price Chart

+48.28% · this period
$3.15$2.44$1.74Apr 13Oct 12Apr 12
Valuation
Market Cap
$108.71M
P/E
-2.42
P/S
0.00
P/B
0.73
EV/EBITDA
0.81
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-26.35%
ROIC
-32.37%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-43,952,000 · -5.53%
EPS
$-1.25 · -5.93%
Op Income
$-48,170,000
FCF YoY
-15.11%
Performance & Tape
52W High
$3.19
52W Low
$1.65
50D MA
$3.09
200D MA
$2.86
Beta
0.10
Avg Volume
167.62K

Get TickerSpark's AI analysis on CYT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 20, 24Leonard Braden Michaelbuy170,589
Mar 18, 24Leonard Braden Michaelbuy113,777
Mar 15, 24Leonard Braden Michaelother0
Mar 15, 24Leonard Braden Michaelother0
Mar 4, 24Gaiero David Gother2,373
Feb 29, 24Gaiero David Gother4,746
Feb 29, 24Gaiero David Gother3,239
Feb 29, 24Gaiero David Gother4,746
Mar 4, 24Gaiero David Gother2,373
Feb 29, 24Gaiero David Gother3,239
Coverage · CYT

Our CYT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CYT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CYT report →
Internal Compare

Similar companies

Peers in the same neighborhood.